1. Home
  2. SWVL vs HOWL Comparison

SWVL vs HOWL Comparison

Compare SWVL & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Swvl Holdings Corp

SWVL

Swvl Holdings Corp

HOLD

Current Price

$1.56

Market Cap

25.8M

ML Signal

HOLD

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

29.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWVL
HOWL
Founded
2017
2017
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
29.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SWVL
HOWL
Price
$1.56
$0.65
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
2.3M
423.0K
Earning Date
04-01-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,329,423.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.32
$0.53
52 Week High
$5.26
$2.38

Technical Indicators

Market Signals
Indicator
SWVL
HOWL
Relative Strength Index (RSI) 39.16 46.95
Support Level $1.53 $0.59
Resistance Level $1.70 $0.74
Average True Range (ATR) 0.22 0.07
MACD -0.03 0.01
Stochastic Oscillator 24.67 28.04

Price Performance

Historical Comparison
SWVL
HOWL

About SWVL Swvl Holdings Corp

Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Share on Social Networks: